[Mirabegron, a breakthrough in overactive bladder syndrome?]

Conclusions: The clinical efficacy of mirabegron is very modest and comparable to that achieved with the other drugs approved for this indication. Moreover, it is more expensive than other therapeutic options. Cardiac risks and urinary infections only allow to consider it as an alternative option to anticholinergic drugs, when these are contraindicated, show no clinical efficacy, or cause unacceptable adverse effects.
PMID: 28478755 [PubMed - in process]

Source: Farmacia Hospitalaria - May 1, 2017 Category: Drugs & Pharmacology Authors: Maestro Nombela A, Almodóvar Carretón MJ, Saavedra Quirós V, Barreda Velázquez C, Jamart Sánchez L Tags: Farm Hosp Source Type: research